Portfolio Management

Expanding Into Asia-Pacific: Life sciences opportunities and strategies for success
Objective :

Management of the client’s Infectious Disease portfolio to ascertain the best course of action for the future clinical and commercial development of therapeutics under the said portfolio, leading to increased ROI

Problem Statement:

A small-Pharma client based in Israel involved DelveInsight to manage their portfolio of candidates indicated for various infectious diseases. The client provided DelveInsight with the task of assessing the best strategic direction for each asset through extensive market research analysis, for development for US and EU regions.

Our Methodology:
  • Infectious Disease Market Assessment
  • Opportunity Assessment for each candidate
  • Unmet Need Analysis of Patients in regions of the client’s interest
  • Market Valuation and Future Trend Overview
Results:
  • Detailed landscaping of the arena in the regions of client’s interest
  • Asset prioritization to segregate assets for development or divestiture
  • Opportunity Assessment to allocate resources for future development
  • Market Assessment to understand Future Market Share

Related Insights

Asset Prioritization
Asset Prioritization

A mid-sized pharma client was working to develop their asset portfolio, and was interested to assess best possible asset for atrial fibrillation [...]

View Case
Go-To-Market Strategy
Go-To-Market Strategy

A medium pharmaceutical client based in United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes [...]

View Case
Competitive Benchmarking
Competitive Benchmarking

A large pharmaceutical client based in Europe involved DelveInsight to identify patient advocacy strategies of companies operating in the Pharma sector of the European Union, to benchmark their efforts against their competitors. [...]

View Case

Fill the form to download the case study

I consent to DelveInsight gathering details provided via this form. Check our Privacy Policy to know more.